Long-acting beta2-agonists in asthma: safety concerns.
作者信息
Wooltorton Eric
出版信息
CMAJ. 2005 Oct 25;173(9):1030-1. doi: 10.1503/cmaj.051224. Epub 2005 Oct 7.
Abstract
摘要
相似文献
1
Long-acting beta2-agonists in asthma: safety concerns.哮喘治疗中长效β2受体激动剂：安全性问题
CMAJ. 2005 Oct 25;173(9):1030-1. doi: 10.1503/cmaj.051224. Epub 2005 Oct 7.
2
Safety of long-acting beta-agonists--an urgent need to clear the air.长效β受体激动剂的安全性——亟待澄清事实
N Engl J Med. 2005 Dec 22;353(25):2637-9. doi: 10.1056/NEJMp058299.
3
Pharmacogenetics of beta(2)-agonists in children.儿童β₂受体激动剂的药物遗传学
J Allergy Clin Immunol. 2009 Dec;124(6):1195-6. doi: 10.1016/j.jaci.2009.09.023.
4
Stopping long-acting beta-2 agonists.停用长效β2受体激动剂。
Med Lett Drugs Ther. 2010 Mar 22;52(1334):21.
5
Salmeterol and formoterol: asthma aggravation. Use should be restricted.沙美特罗和福莫特罗：可加重哮喘。应限制使用。
Prescrire Int. 2009 Aug;18(102):166.
6
State of the art in beta2-agonist therapy: a safety review of long-acting agents.β2 激动剂治疗的现状：长效制剂的安全性综述
Int J Clin Pract. 2003 Oct;57(8):689-97.
7
[Long-acting beta2-agonist bronchodilators safety for asthma treatment].长效β2受体激动剂支气管扩张剂用于哮喘治疗的安全性
Arch Argent Pediatr. 2009 Aug;107(4):291-3. doi: 10.1590/S0325-00752009000400002.
8
Asthma: fatal exacerbations with long-acting beta2 agonist therapy without concomitant steroid therapy.哮喘：长效β2受体激动剂治疗且未同时使用类固醇治疗时的致命性加重。
Prescrire Int. 2007 Apr;16(88):69-70.
9
[Comments of the German Airway League and the German Respiratory Society to the US Food and Drug Administration (FDA)'s announcement from February 18th 2010 on the use of long acting beta-2 agonists in treatment of asthma].[德国气道联盟和德国呼吸学会对美国食品药品监督管理局（FDA）2010年2月18日关于长效β2受体激动剂用于哮喘治疗的公告的评论]
Pneumologie. 2010 Jun;64(6):333-5. doi: 10.1055/s-0029-1244230. Epub 2010 Jun 7.
10
Long acting β2 agonists in adult asthma.长效β2受体激动剂在成人哮喘中的应用
BMJ. 2013 Aug 6;347:f4662. doi: 10.1136/bmj.f4662.
引用本文的文献
1
In vitro allergen challenge of peripheral blood induces differential gene expression in mononuclear cells of asthmatic patients: inhibition of cytosolic phospholipase A2alpha overcomes the asthma-associated response.外周血的体外过敏原激发可诱导哮喘患者单核细胞中的基因表达差异：抑制胞质磷脂酶A2α可克服哮喘相关反应。
Clin Exp Allergy. 2008 Oct;38(10):1590-605. doi: 10.1111/j.1365-2222.2008.03059.x. Epub 2008 Jul 28.
2
SMART therapy.智能疗法
CMAJ. 2006 Aug 1;175(3):276-7. doi: 10.1503/cmaj.1060124.
本文引用的文献
1
Canadian Pediatric Asthma Consensus guidelines, 2003 (updated to December 2004): introduction.《2003年加拿大儿童哮喘共识指南》（更新至2004年12月）：引言
CMAJ. 2005 Sep 13;173(6 Suppl):S12-4. doi: 10.1503/cmaj.045064.
2
Serious asthma exacerbations in asthmatics treated with high-dose formoterol.接受高剂量福莫特罗治疗的哮喘患者的严重哮喘加重情况。
Chest. 2003 Jul;124(1):70-4. doi: 10.1378/chest.124.1.70.
3
Salmeterol (Serevent) asthma trial halted early.沙美特罗（施立稳）哮喘试验提前终止。
CMAJ. 2003 Mar 18;168(6):738.
4
Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment.施立稳全国性监测研究：沙美特罗与沙丁胺醇在需要常规支气管扩张剂治疗的哮喘患者中的比较
BMJ. 1993 Apr 17;306(6884):1034-7. doi: 10.1136/bmj.306.6884.1034.
Zotero 插件